ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.996,63
0,89%
S&P 500
5.728,30
0,17%
Dow Jones
42.153,93
0,07%
Euro vs US Dollar
1,11657
0,49%
Bitcoin
63.807,37
0,76%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Okyo Pharma Limited (OKYO)

  7. Okyo Pharma Limited (OKYO) News

OKYO

Okyo Pharma (OKYO)

Okyo Pharma Limited
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:OKYO
DatumZeitQuelleÜberschriftSymbolFirma
10/09/202413h00UK RegulatoryOKYO Pharma Announces Chairman Acquires SharesLSE:OKYOOkyo Pharma Limited
05/09/202413h00UK RegulatoryOKYO Pharma Announces Chairman Acquires SharesLSE:OKYOOkyo Pharma Limited
27/08/202413h00UK RegulatoryOKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye DiseaseLSE:OKYOOkyo Pharma Limited
23/08/202415h00UK RegulatoryOKYO Pharma CEO Interview to Air on Bloomberg TVLSE:OKYOOkyo Pharma Limited
23/08/202413h00UK RegulatoryOKYO Pharma Announces Chairman Acquires SharesLSE:OKYOOkyo Pharma Limited
21/08/202413h00UK RegulatoryOKYO Pharma Announces Chairman Acquires SharesLSE:OKYOOkyo Pharma Limited
15/08/202418h13UK RegulatoryOKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceLSE:OKYOOkyo Pharma Limited
06/08/202413h00UK RegulatoryOKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of UseLSE:OKYOOkyo Pharma Limited
11/07/202413h00UK RegulatoryOKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101LSE:OKYOOkyo Pharma Limited
10/07/202413h00UK RegulatoryOKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye DiseaseLSE:OKYOOkyo Pharma Limited
08/05/202413h00UK RegulatoryOKYO Pharma Announces Participation in May 2024 Investor ConferencesLSE:OKYOOkyo Pharma Limited
30/04/202413h00UK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)LSE:OKYOOkyo Pharma Limited
09/04/202401h00UK RegulatoryOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024LSE:OKYOOkyo Pharma Limited
02/04/202413h00UK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryLSE:OKYOOkyo Pharma Limited
22/03/202412h00UK RegulatoryOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101LSE:OKYOOkyo Pharma Limited
21/03/202412h00UK RegulatoryOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialLSE:OKYOOkyo Pharma Limited
20/03/202412h00UK RegulatoryOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventLSE:OKYOOkyo Pharma Limited
09/02/202413h36InvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
09/02/202413h00UK RegulatoryOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
31/01/202413h00UK RegulatoryOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardLSE:OKYOOkyo Pharma Limited
22/05/202309h15UK RegulatoryOKYO Pharma Limited London Stock Exchange DelistingLSE:OKYOOkyo Pharma Limited
22/05/202309h00UK RegulatoryLondon Stock Exchange Notice Cancellation - OKYO PHARMA LIMITEDLSE:OKYOOkyo Pharma Limited
19/05/202312h22Alliance NewsAlliance NewsIN BRIEF: Okyo Pharma to move shares to New York with London delistingLSE:OKYOOkyo Pharma Limited
19/05/202309h00RNS Non-RegulatoryOKYO Pharma Limited ADS Program collapseLSE:OKYOOkyo Pharma Limited
15/05/202308h00UK RegulatoryOKYO Pharma Limited Change of Record Time and Last Day of DealingsLSE:OKYOOkyo Pharma Limited
11/05/202315h27Alliance NewsAlliance NewsIN BRIEF: Okyo Pharma delays delisting from London trading to May 22LSE:OKYOOkyo Pharma Limited
11/05/202313h00RNS Non-RegulatoryOKYO Pharma Limited Webull Corporate Communications Service PlatformLSE:OKYOOkyo Pharma Limited
11/05/202308h00UK RegulatoryOKYO Pharma Limited Change of Delisting Date to 22 May 2023LSE:OKYOOkyo Pharma Limited
03/05/202314h00UK RegulatoryOKYO Pharma Limited Result of MeetingLSE:OKYOOkyo Pharma Limited
03/05/202308h00RNS Non-RegulatoryOKYO Pharma Limited Presentation on OK-101 at ASCRSLSE:OKYOOkyo Pharma Limited
 Showing the most relevant articles for your search:LSE:OKYO

Kürzlich von Ihnen besucht

COIN
ADAUSD
Cardano
NASDAQ
AMZN
Amazon.com
FX
EURUSD
Euro vs US Dollar
TG
ALV
Allianz
TG
BAS
BASF
DBI
MDAX
MDAX
TG
TUI1
Tui
AMEX
XLV
Health Care Select Sector
NYSE
DIS
Walt Disney
DBI
DAX
DAX
COIN
BTCUSD
Bitcoin
CCOM
SILVER
SILVER
NASDAQ
TSLA
Tesla
TG
RHM
Rheinmetall
FX
EURGBP
Euro vs Sterling
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten